Phillips Scott B. 4
4 · Winston Pharmaceuticals, Inc. · Filed May 5, 2009
Insider Transaction Report
Form 4
Phillips Scott B.
DirectorSVP, Scientific Affairs
Transactions
- Exercise/Conversion
Common Stock
2009-05-01$0.28/sh+158,859$44,481→ 656,657 total - Exercise of In-Money
Common Stock Options
2009-05-01−158,859→ 0 totalExercise: $0.28From: 2000-05-03Exp: 2009-05-03→ Common Stock (158,859 underlying)
Footnotes (2)
- [F1]Effective December 15, 2008 (the "Effective Date") the Company effectuated a 1-for-8 reverse stock split whereby each eight shares of Winston Pharmaceuticals, Inc.'s (the "Company's") common stock and preferred stock either issued and outstanding or held as treasury shares immediately prior to the Effective Date were automatically reduced and continued as one share of the Company's common stock or preferred stock, as applicable. All of the Company's outstanding securities were adjusted accordingly to reflect such reverse split.
- [F2]Reported amount excludes: (i) options to purchase 397,147 shares of the Company's common stock, initially exercisable on 10/18/2000 and expiring on 10/18/2009, at an exercise price of $0.28; (ii) options to purchase 205,193 shares of the Company's common stock, initially exercisable on 12/10/2003 and expiring on 12/10/2012, at an exercise price of $0.33; (iii) options to purchase 231,670 shares of the Company's common stock, initially exercisable on 01/12/2005 and expiring on 01/12/2014, at an exercise price of $0.33; (iv) options to purchase 661,913 shares of the Company's common stock, initially exercisable on 04/06/2006 and expiring on 04/06/2015, at an exercise price of $0.34.